ipamorelin human clinical trials CJC-1295 + Ipamorelin ipamorelin clinical trial trials humans

The peptide has been extensively studied in both preclinical models and human clinical trials, demonstrating consistent fat-reducing effects with a favorable safety profile

Thiopurines indicated for mild to moderate UC cases that had recurrent relapses with corticosteroids

Nucleic Acids Res 18: 6069-6074

doi: 10.1016/j.celrep.2022.111724 35

The Goal-Phased Annual Protocol Plan the full year in advance around research priorities: Sample Annual Peptide Rotation Framework Q1 (JanMar): GH optimization phase CJC-1295 + Ipamorelin stack Q2 (AprMay): Off GH peptides, acute Epithalon cycle + Selank for cognitive focus Q3 (JunAug): Body composition/recovery phase BPC-157 or TB-500 as needed, reintroduce GH stack Q4 (SepDec): Off GH peptides again, optional PT-141 or GHK-Cu phase Stacking Peptides Within a Cycle Cycling different peptides doesn't mean running only one at a time